stockrowGrifols, S.A. (GRFS) vs Novo Nordisk A/S (NVO)
- Grifols, S.A. GRFS 8.43 −0.35%
- Novo Nordisk A/S NVO 40.31 +0.02%
Grifols, S.A. and Novo Nordisk A/S are both Drug Manufacturers General companies. Novo Nordisk A/S is the larger, with a market value of $134.8B against $2.2B — 61.9× the size. Novo Nordisk A/S trades at the lower P/E: 10.1× against 18.2×. Novo Nordisk A/S grew revenue faster over the last twelve months: 11.1% against 10.9%. Novo Nordisk A/S has the higher net margin (34.1% vs 6.02%) and the higher return on invested capital (29.6% vs 4.76%). Both pay a dividend; Novo Nordisk A/S yields more (4.46% vs 1.12%). Across the 23 metrics below, Novo Nordisk A/S leads on 16 and Grifols, S.A. on 7.
Valuation
Profitability
| Metric | GRFS | NVO | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 37.55% | 80.89% | 73.01% |
| Operating margin | 16.69% | 42.66% | 18.34% |
| Net margin | 6.02% | 34.09% | 7.31% |
| Free cash flow margin | 8.51% | 13.25% | 18.56% |
| Return on equity | 5.80% | 58.84% | 5.80% |
| Return on assets | 2.28% | 20.52% | 2.28% |
| Return on invested capital | 4.76% | 29.63% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack